After years of regulatory limbo, the US Food and Drug Administration (FDA) has finally released its long-anticipated draft guidance on the regulation of hemp-derived cannabidiol (CBD) in food and dietary supplements. Published on 10 March 2026, the proposed framework marks the agency’s most definitive stance to date on the $4 billion-plus US CBD market, seeking to treat non-intoxicating hemp extracts as legal food ingredients while imposing strict safety and labelling requirements.
What the Draft Guidance Proposes
The 87-page document, titled ‘Dietary Supplements and Conventional Foods Containing Hemp-Derived CBD: Draft Guidance for Industry’, outlines a pathway for CBD to be marketed as a dietary supplement or food additive—provided manufacturers meet rigorous new standards. Key provisions include a maximum daily serving limit of 20 milligrams of CBD per adult, mandatory third-party testing for contaminants such as heavy metals and pesticides, and explicit prohibitions on health claims linking CBD to disease treatment or prevention. The FDA also proposes that all products carry a warning label stating: ‘This product contains CBD. Consult a physician before use, especially if pregnant, nursing, or taking medication.’ The draft guidance is open for public comment until 10 June 2026, with a final rule expected by early 2027.
Industry Reactions: Cautious Optimism and Sharp Criticism
Reactions from the CBD sector have been mixed. The US Hemp Roundtable, an industry advocacy group, praised the FDA for ‘finally providing a clear regulatory path’ but expressed concern that the 20 mg cap was too low to capture the market’s potential. ‘This limit would effectively restrict most tinctures and gummies to sub-therapeutic doses,’ said CEO Jonathan Miller in a statement. Conversely, the Consumer Healthcare Products Association (CHPA) warned that the framework could ‘stifle innovation’ by requiring expensive new safety studies for existing products. Meanwhile, public health advocates, including the Centre for Science in the Public Interest, welcomed the move, arguing that long-term oversight was ‘urgently needed to protect consumers from unsubstantiated claims and variable product quality.’
What This Means for the US CBD Market
The draft guidance arrives at a critical juncture for an industry that has operated in a grey area since the 2018 Farm Bill legalised hemp. Without formal FDA rules, many retailers—including major pharmacy chains—have refused to stock ingestible CBD products, stifling growth. Analysts at Brightfield Group estimate that the US CBD market could expand by 40% to $6 billion by 2028 if the final rule is adopted with reasonable compliance costs. However, smaller producers may struggle: the proposed testing and labelling requirements could cost up to $50,000 per product line, potentially consolidating the market among larger players. The FDA has also signalled it will begin enforcement actions against companies making unsubstantiated therapeutic claims once the final rule is enacted, a move that could trigger a wave of product reformulations. For consumers, the guidance promises increased transparency and safety, but also higher prices as compliance costs are passed down the supply chain. The next three months of public comment will determine whether this framework becomes the industry’s new foundation—or a flashpoint for further litigation.
